EGFR and neoplasm: The Two-in-One antibody demonstrated specific cellular binding properties on EGFR- and PD-L1-expressing tumor cells, as well as inhibition of EGFR-dependent signal transduction and blockage of the PD-1/PD-L1 interaction.